Module 2 Eligibility for a TAS TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of.

Slides:



Advertisements
Similar presentations
MICS4 Survey Design Workshop Multiple Indicator Cluster Surveys Survey Design Workshop Household Questionnaire: Insecticide Treated Nets and Indoor Residual.
Advertisements

SADC Course in Statistics Samples and Populations (Session 02)
Module 10 Field work TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass drug.
Module 5 Diagnostic tests
5-1-1 Unit 1: Introduction to the course and to behavioural surveillance.
1 Analyzing HIV Prevalence Trends from Antenatal Clinic (ANC) Sentinel Surveillance Data and Serosurveillance Data from High Risk Groups* Ray Shiraishi.
Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis Module 4 Survey design.
Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis Module 1 Background.
Module 6 After the survey TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass.
HIV/AIDS DEPARTMENT 2013 Consolidated ARV Guidelines Treatment Recommendations for Pregnant and Breastfeeding Women: Critical Issues Dr. Nathan Shaffer.
PROGRESS REPORT: The National STH Programme in BHUTAN Mr. Sangay Thinley 2014 RPRG Meeting Jakarta, Indonesia 23 – 24 Sept
Directorate of National Vector Borne Disease Control Programme Directorate General of Health Services Ministry of Health & Family Welfare, Delhi (India)
Malaria Elimination in Zanzibar. Introduction Dramatic declines in malaria morbidity and mortality over the last decade (prevalence remained
Progress report: the National LF and STH programme in MYANMAR Dr. Ni Ni Aye, Program Manager (ELF) LF and STH program Mangers Meeting,Jakarta (23-24 sept,2014)
Module 3 Evaluation unit
Module 4: Final Case Study # 4-CS-1. Case Study: Instructions v Try this case study individually. v We’ll discuss the answers in class. # 4-CS-2.
Malaria in Zambia A refresher Scope of Presentation  Background on Malaria  Overview of malaria in Zambia  Interventions  Impact  Active Case.
Monitoring progress towards the coverage and disease incidence targets GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING March 2011 Geneva, Switzerland.
Module 8 Survey sample builder
Dr Ahmed Jamsheed Mohamed WHO South East Asia Regional Office 9-11 February 2015.
Eliminating Lymphatic Filariasis in the Americas A Winnable Battle Center for Global Health Division of Parasitic Diseases and Malaria.
Unit 5: Core Elements of HIV/AIDS Surveillance
Proceedings of the SAGE Working Group on Rubella Vaccines Susan E. Reef, MD Global Measles and Rubella Management Meeting March 15, 2011.
Chapter 13 Survey Designs
Unit 4: Monitoring Data Quality For HIV Case Surveillance Systems #6-0-1.
Module 9 Timetable, budget and administration TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological.
Module 3: Final Case Study # 3-CS-1. Case Study: Instructions v Try this case study individually. v We’ll discuss the answers in class. # 3-CS-2.
Power Point Slides by Ronald J. Shope in collaboration with John W. Creswell Chapter 13 Survey Designs.
Power Point Slides by Ronald J. Shope in collaboration with John W. Creswell Chapter 13 Survey Designs.
Data Requirements for Field Release and Monitoring Jon Knight Imperial College London
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Post-MDA surveillance ( including xeno-monitoring) Krishnamoorthy K. Vector Control Research Centre Pondicherry India.
Dr Godfrey Xuereb Team Leader Surveillance and Population-based Prevention Department for the Prevention of NCDs A comprehensive global monitoring framework.
Lymphatic Filariasis By Morgan McBride.
1 What are Monitoring and Evaluation? How do we think about M&E in the context of the LAM Project?
Slide 1 Long-Term Care (LTC) Collaborative PIP: Medication Review Tuesday, October 29, 2013 Presenter: Christi Melendez, RN, CPHQ Associate Director, PIP.
Roadmap Progress Report 2011 Zambia SARN-RBM PARTNERS ANNUAL CONSULTATIVE MEETING, JULY 2011.
Session 3: Assessment & Evaluation Lisa Jacques-Carroll, MSW NCIRD, CDC.
Zambia National Malaria Indicator Survey (MIS) 2010 Welcome!! The Barn Motel Lusaka.
EPIDEMIOLOGY DENGUE, MALARIA Priority Areas for Planning Dengue Emergency Response 1. Establish a multisectoral dengue action committee.
Module 7 Verification of elmination TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment.
Assessing the Feasibility of Continuous Net Distribution in Kenya using Community Based Approach.
Sampling Techniques. Simple Random Sample Keep Your Index Card Number On You Table 1 – Random Numbers
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
21/4/2008 Evaluation of control measures 1. 21/4/2008 Evaluation of control measures 2 Family and Community Medicine Department.
Data Triangulation Applications in Population and Health Programs- -The Global Experience.
Global burden of LF Around 1.4 billion people in 73 countries at risk Over 120 million infected About 40 million disfigured and incapacitated.
Unit 6: Specialised Techniques: Anti-Microbial Resistance Monitoring and Assessment of STI Syndrome Aetiologies #4-6-1.
Progress Report: National LF and STH Programme in Nepal
Progress report: the national LF and STH programme in Thailand By Sunsanee Rojanapanus, Dr. Thitima Wongsaroj 2014 RPRG Meeting WHO Region.
Mohamed Faisal 2014 RPRG Meeting WHO Region.  Geography and Population ◦ Total population: 371,507 (Census 2006) ◦ Ecological zones – next slide  Political.
Copyright © 2008 by Pearson Education, Inc. Upper Saddle River, New Jersey All rights reserved. John W. Creswell Educational Research: Planning,
Working to overcome the global impact of neglected tropical diseases Documenting the achievement of elimination as a public health problem GPELF dossier.
"Epidemiological Features of Rotavirus Infection among children below 5 years old in Jordan, Rationale for Vaccine Introduction,2015" Kareman Juma`ah Al-Zain.
IMPLEMENTATION AND PROCESS EVALUATION PBAF 526. Today: Recap last week Next week: Bring in picture with program theory and evaluation questions Partners?
Sayed Ali Mus POST GRADUATES-BATCH 6 FACULTY OF MEDICAL LABORATORY SCIENCES PARASITOLOGY DEPARTMENT ALNEELIN UNIVERSITY March 2015 Symposium on: Advances.
A Workshop for Data Entry Clerks
Quality issues in monitoring diagnostic and treatment performance Dr
Presenter: Christi Melendez, RN, CPHQ
APPMG December 17, 2008 Presented by Dr. John P. Rumunu (MPH, MB.BS)
Where we could be by 2015 and how to get there
Elimination of lymphatic filariasis
Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a.
Training Workshop – Module 3
Cost-effectiveness of scaling up mass drug administration for the control of soil- transmitted helminths: a comparison of cost function and constant costs.
Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a.
Mectizan Donation for IDA countries
Developing Sustainable Projects
RTI International Daniel A. Cohn Sr Technical Advisor
Presentation transcript:

Module 2 Eligibility for a TAS TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis Module 2 Eligibility for a TAS

Learning objectives By the end of this module, you should understand that the eligibility of an IU for a TAS is assessed on the basis of: 1.epidemiological drug coverage (programme coverage) 2.prevalence of infection at sentinel sites 3.prevalence of infection at spot-check sites Slide 2

Module 2 Eligibility for a TAS Overview  Eligibility criteria for a TAS  Epidemiological drug coverage (programme coverage)  Sentinel and spot-check surveys  Confirming eligibility Slide 3

Module 2 Eligibility for a TAS Eligibility criteria for a TAS Slide 4 In order for a national programme to start planning a TAS, the following criteria must be met in each IU:  At least five rounds of MDA were completed.  ≥ 65% epidemiological drug coverage achieved at each round.  Sentinel site: prevalence of Mf < 1% or prevalence of Ag < 2% after last effective round at all sites  Spot-check site: prevalence of Mf < 1% or prevalence of Ag < 2% after last effective round at all sites

Module 2 Eligibility for a TAS Epidemiological drug coverage  Epidemiological drug coverage (programme coverage) is defined as "the proportion of individuals in an IU who actually ingested the medicines" No. people reported to have ingested the medicines Total population in IU X 100 =  To reduce the prevalence of Mf in infected individuals to the threshold below which transmission is assumed to be no longer sustainable, at least 65% of the total population in each IU must ingest the medicines in at least five rounds of MDA. Slide 5

Module 2 Eligibility for a TAS Sentinel and spot-check surveys Slide 6  Blood surveys at sentinel sites are used to establish the baseline infection level and to monitor the impact of MDA on infection prevalence periodically.  Once a sentinel site is selected, it should continue to serve as the sentinel site throughout the programme.  Blood surveys at spot-check sites are used to confirm that the results of sentinel surveys represent the infection level in the entire IU.  At least one spot-check site is selected for each sentinel site.

Module 2 Eligibility for a TAS How many sentinel and spot-check sites are needed in each implementation unit? Slide 7  At least one sentinel site per 1 million people  At least one sentinel site in each IU; more sites may be selected when resources allow  Smaller IUs may be served by one sentinel site.  Combined IUs should be contiguous and have similar epidemiological characteristics.  Combined IUs should have conducted MDA at the same time.  The advice of WHO and the RPRG may be required.

Module 2 Eligibility for a TAS Characteristics of sentinel and spot-check sites Slide 8  The population should be at least 500 people (to collect samples from at least 300 people aged > 5 years)  Should be in an area of high transmission: high disease or parasite prevalence or vector abundance  or an area where difficulty in achieving high drug coverage is anticipated  No prior MDA for onchocerciasis  A stable population

Module 2 Eligibility for a TAS When should surveys be conducted? Slide 9  Baseline assessment: before first MDA  Mid-term evaluation: at least 6 months after third MDA (optional)  Follow-up survey: at least 6 months after fifth effective MDA Mapping TAS Mf and/or Ag prevalence (baseline) Mf and/or Ag prevalence (follow-up) Mf and/or Ag prevalence (optional) Round of MDA

Module 2 Eligibility for a TAS Slide 10  Target population  Convenience sample of at least 300 people  All members of the population in all age groups > 5 years (including pregnant women)  When the population is too large, a part can be chosen.  Diagnostic test  Blood film for prevalence of Mf  Immunochromatographic test (ICT) for Ag rate if resources allow (in W. bancrofti areas) When should surveys be conducted?

Module 2 Eligibility for a TAS Confirming eligibility to conduct a TAS Slide 11  Before assessing the eligibility of an IU, programme managers should compile all necessary records and complete the ‘INTRO’ and ‘ELIGIBILITY’ worksheets of the TAS Eligibility and Reporting Form.  The form helps in deciding whether the time is appropriate to conduct a TAS.  The form should be reviewed by the RPRG before the survey is planned.